Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News TCT 2016

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2016

Shelley Wood

July 28, 2016

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

News Industry News

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

July 22, 2015

News Conference News TCT 2014

EVERBIO II: Angiographic Outcomes Similar for BVS, EES, BES

September 17, 2014

News Daily News

Carbon Dioxide Angiography May Be Alternative to Iodinated Contrast in High-Risk Patients

L.A. McKeown

August 16, 2011

Advertisement

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

TCTMD’s Top 10 Most Popular Stories for July 2016

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

EVERBIO II: Angiographic Outcomes Similar for BVS, EES, BES

Carbon Dioxide Angiography May Be Alternative to Iodinated Contrast in High-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content